[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Biobanking For Medicine: Technology And Market 2013-2023

March 2013 | 158 pages | ID: BE920F9BBABEN
Visiongain

US$ 2,635.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Report Details

Biobanks - what are their technological and commercial prospects?

See what the future holds for biobanking in human medicine. Visiongain's updated report gives you its revenue predictions to 2023. There you see sales data, technological trends, opportunities and financial prospects.

Our study shows you the potential of technologies, products and services for that archiving of medical biosamples. In that work you see forecasted sales at overall world market, submarket and national level. Discover what's likely to happen from 2013.

In biobanking, many opportunities remain, especially for pharmaceutical applications. In our work you discover which areas can most develop and prosper. Read on to scan crucial features of that industry, find what drives it, and see what its future market could be worth.

Forecasts and other analyses to help you find the best growth opportunities

In our study you find revenue forecasting to 2023, historical data, growth rates and market shares. There you assess quantitative and qualitative analysis, business news, outlooks and developmental trends. You gain 47 tables, 44 charts and seven full research interviews.

Our work lets you investigate the most promising and lucrative aspects of biorepositories, biotrusts and biolibraries, helping you stay ahead in knowledge. That way, you reduce the risk of your missing out.

See, then, the future of preserving biosamples to benefit medicine. The following sections show what you discover there in our new report.

Find sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market, you see forecasts to 2023 for three main biobanking submarkets:
  • Human tissue samples
  • Stem cells and related biorepository material
  • Other biopreservation - including DNA, RNA and body fluids.
Our study breaks the human tissues segment into these further divisions, with forecasts to 2023:
  • Commercial biorepositories - service-providing companies
  • Public-sector storage facilities - hospitals, clinics, research institutes and universities.
For stem cell banking, our analysis breaks that segment into these divisions, with forecasts to 2023:
  • Cord blood storage
  • Other biological sample archives.
Our investigation also discusses what stimulates and restrains business for medical sample preservation. In our work you find dynamics of that healthcare industry and assess its potential sales, seeing what's likely to achieve the most success.

That study also divides its overall world revenue forecast into those for the main geographical markets.

What prospects for leading regions and countries?


Developments worldwide will influence the biobanking industry and market, especially rising demand for those services in emerging countries - particularly India and China.

In developed and developing countries there exist many opportunities for medical biosample archiving. Our work shows potentials there. You see prospects for supplying and using storage facilities in biopreservation. Also, you see opportunities for biomedical industries.

Our analyses thus show you individual revenue forecasts to 2023 for eleven national markets:
  • US
  • Japan
  • Germany, France, UK, Italy and Spain (EU5)
  • Brazil, Russia, India and China (BRIC).
There you discover progress and outlooks. That way you assess the industry's future - hear about developments and find their significance. Our work explains, exploring many issues.

What affects the biobanking industry and market?

Our study lets you assess trends and outlooks. There, you find discussions of issues and developments:
  • Rising demand for biobanking resources
  • Biobank networks and collaborations
  • Pharma and biotech companies' in-house sample storage systems
  • Distribution of biosample repositories worldwide and scale of operations
  • Population- and disease-orientated biosample storage
  • Ownership, funding and governmental support of the facilities
  • Ethics, guidelines, regulations and legislation, including quality standards
  • Standardisation of processes - challenges and opportunities.
Our work also discusses these aspects of the field:
  • Uses to support drug and biomarker discovery
  • Applications in medical research and drug development
  • Collection and storage of genomic material, esp. DNA banking
  • Human embryonic (hESC) and induced pluripotent (iPSCs) stem cells
  • Cancer-cell banking services and applications in oncology
  • Security and ownership of biospecimens
  • Relevance of the processes to in vitro testing and molecular diagnostics.
The study covers supporting technology too:
  • Automated liquid handling, frozen aliquotting and ultra-low temperature freezing
  • Dry-state, room-temperature storage
  • Energy conservation in biorepositories
  • Consumables, RFID and tagging technologies
  • Automated storage and retrieval systems for operational efficiency
  • Software and laboratory information management systems (LIMS).
That way, you explore technological, economic, social and political (STEP) questions, assessing outlooks for that area of business. You also analyse the industry's strengths, weaknesses, opportunities and threats (SWOT).

Our report thus lets you assess the potential of biomedical storage and archiving to aid molecular, cellular and tissue-based research. See, then, what the future holds.

Leading companies and 2017 market value

What happens next? Our study predicts the world market for human medical biobanking will reach $24.4bn in 2017, and expand strongly to 2023.

Our report shows you what activities and organisations there hold potential. Its analyses cover these prominent companies:
  • Tissue Solutions
  • Asterand
  • Biopta
  • BioServe
  • Cord Blood America
  • Cryo-Cell International
  • Cryo-Save.
Our work also analyses these participants, and discusses other companies:
  • China Cord Blood Corporation
  • LifebankUSA
  • Stem Cell Authority
  • ViaCord
  • Biogenea
  • StemLife
  • Future Health Biobank
  • NeoStem.
In our study you find 210 organisations mentioned. Also, you read seven interviews with authorities in the field. See who shapes it, discovering what they think, do and say.

Prospects for biobanking are strong, and from 2013 onwards there will arise many opportunities. Our work shows you its prospects, helping you stay ahead.

Eight ways Biobanking for Medicine: Technology and Market 2013-2023 helps you

To sum up, our investigation gives you the following knowledge:
  • Revenues to 2023 for the world market for medical biobanks - you discover that industry's sales prospects
  • Revenues to 2023 for 7 world-level submarkets - you discover the potential of its segments, finding the most promising areas for investments and revenues
  • Forecasts to 2023 for US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China - you see national sales potentials, finding the best regions for revenues and growth
  • Profiles of 15 leading companies - you hear about strategies, capabilities, results and outlooks
  • Interviews with leaders in the industry - you discover debates and opinions to help you stay ahead
  • Competition and opportunities - you see what affects that industry, learning what shapes its future, esp. prospects for sustaining and developing business
  • Analysis of what stimulates and restrains the industry and market - you assess challenges and strengths, helping you compete and gain advantages
  • Prospects for established competitors and organisations seeking to enter the sector - you explore needs, practices and outlooks for future success.
You gain information found nowhere else

That work gives independent analysis. There you receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses and decisions, also saving time and getting you recognition for technological and commercial insight.

Our knowledge costs only a tiny fraction of potential profits from your understanding and harnessing that market. See its growth potential and find what you can gain.

Ordering now lets you discover crucial predictions for 2013 onwards

Our investigation is for everyone needing analysis of the industry and market for biobanking. There you find data, trends, opportunities and predictions. Please order our report now
1. EXECUTIVE SUMMARY

1.1 Main Findings of this Report
1.2 Aims, Scope and Format of the Report
  1.2.1 Chapter Outlines
  1.2.2 On Assessing the Biobanking Industry and Market
1.3 Research and Analysis Methods
  1.3.1 Human Tissue Banking Market
  1.3.2 Stem Cell Banking Market

2. INTRODUCTION TO BIOBANKING

2.1 Biobanking
  2.1.1 Processes Involved in Biobanking
2.2 Biobanks: A Two-Fold Character
2.3 Key Features
2.4 Classification of Biobanks
  2.4.1 Volunteer Groups
    2.4.1.1 Population-Based Biobanks
    2.4.1.2 Disease-Oriented Biobanks
  2.4.2 Ownership or Funding Structure
2.5 Guidelines and Standards
  2.5.1 Guidelines for Biobanks and Use of Biological Samples for Research
  2.5.2 Industry Standards for Biobanks
  2.5.3 Biobanking Processes Governed by Guidelines
2.6 Laws and Regulations for Biobank-Based Research
  2.6.1 HIPAA Amendments

3. BIOBANKING AND THE PHARMACEUTICAL INDUSTRY

3.1 Scientific and Commercial Use of Biobanking in the Pharmaceutical Industry
  3.1.1 Research and Drug Development
    3.1.1.1 Understanding Disease Pathways
    3.1.1.2 Drug Discovery
    3.1.1.3 Biomarker Discovery
  3.1.2 Therapeutics
  3.1.3 Clinical Trials
3.2 Biobanks Operated by Pharmaceutical Companies

4. THE WORLD MEDICAL BIOBANKING MARKET, 2013-2023

4.1 The World Medical Biobanking Market in 2012
4.2 Revenue Forecast for the World Medical Biobanking Market, 2013-2023
4.3 Biobanking Networks
  4.3.1 Biobanking Networks in Europe
    4.3.1.1Biobanking and Biomolecular Resources Research Infrastructure (BBMRI)
4.4 Commercial Biobanks: New Resources for Research
4.5 Growing Demand for Biobank Resources

5. THE HUMAN TISSUE BANKING MARKET TO 2023

5.1 The Overall Human Tissue Banking Market, 2012-2023
  5.1.1 The Human Tissue Banking Market in 2012
  5.1.2 Human Tissue Banking: Market Forecast, 2013-2023
5.2 The Human Tissue Banking Market: Commercial vs. Public Sector
5.3 Revenue Forecast for the Human Tissue Banking Market by Type of Biobank, 2013-2023
  5.3.1 Commercial Human Tissue Banks: Market Forecast, 2013-2023
  5.3.2 Public Sector and Other Human Tissue Banks: Market Forecast, 2013-2023

6. THE STEM CELL BANKING MARKET TO 2023

6.1 The Overall Stem Cell Banking Market, 2012-2023
  6.1.1 The Stem Cell Banking Market in 2012
  6.1.2 Stem Cell Banking: Market Forecast, 2013-2023
6.2 Stem Cell Banks for Research: High Growth Possible
6.3 Stem Cell Banking and its Submarkets
  6.3.1 Umbilical Cord Blood Banking: A Key Submarket
    6.3.1.1 Blood Banks: Private vs. Public
    6.3.1.2 Umbilical Cord Banking: The Controversies
  6.3.2 Submarkets of Stem Cell Banking: Revenue Forecasts, 2013-2023
    6.3.2.1 Revenue Forecast for Private Cord Blood Banking Market, 2013-2023

7. LEADING NATIONAL MARKETS TO 2023

7.1 Geographical Footprint
  7.1.1 Biobanks in Europe
  7.1.2 Biobanks in the US
  7.1.3 Biobanks in Asia
7.2 Biobanking for Medicine: Leading National Markets in 2012
7.3 Leading National Markets: Forecasts to 2023
  7.3.1 The US Medical Biobanking Market, 2012-2023
  7.3.2 The Leading European Medical Biobanking Markets, 2012-2023
  7.3.3 The Japanese Medical Biobanking Market, 2012-2023
  7.3.4 The Chinese Medical Biobanking Market, 2012-2023
  7.3.5 The Indian Medical Biobanking Market, 2012-2023
  7.3.6 The Brazilian Medical Biobanking Market, 2012-2023
  7.3.7 The Russian Medical Biobanking Market, 2012-2023

8. BIOBANKING ASSOCIATED MARKET: SYSTEMS, SOFTWARE, CONSUMABLES AND SERVICES ASSOCIATED WITH BIOBANKING

8.1 Overview
8.2 Systems and Technologies
  8.2.1 Automated Liquid Handling
  8.2.2 Frozen Aliquotting: New Technology
8.3 Storage
  8.3.1 Ultra-Low Temperature Freezing
  8.3.2 Dry-State, Room-Temperature Storage
  8.3.3 RFID and Tagging Technologies
  8.3.4 Automated Storage and Retrieval Systems
8.4 Software
  8.4.1 Laboratory Information Management System (LIMS)
    8.4.1.1 LIMS Functions
8.5 Consumables
  8.5.1 Addressing Sample Storage and Tracking Issues
8.6 Services

9. LEADING COMPANIES IN THE MARKET

9.1 Business Models of Companies in the Biobanking Market
9.2 Commercial Participants in the Human Tissue Banking Market
  9.2.1 Tissue Solutions
    9.2.1.1 Overview
    9.2.1.2 Global Presence
    9.2.1.3 Products and Services
      9.2.1.3.1 Banked Samples
      9.2.1.3.2 Prospective Samples
      9.2.1.3.3 Fresh Samples
      9.2.1.3.4 Freshly Isolated and Primary Cells
      9.2.1.3.5 FDA/ EMEA Panel of Normal Tissues
      9.2.1.3.6 Services
    9.2.1.4 Strengths and Capabilities
    9.2.1.5 Future Outlook
  9.2.2 Asterand
    9.2.2.1 Overview
    9.2.2.2 Products and Services
      9.2.2.2.1 XpressBANK
      9.2.2.2.2 ProCURE
      9.2.2.2.3 PhaseZERO
    9.2.2.3 Asterand: Raised Barriers for New Market Entrants?
    9.2.2.4 Geographical Distribution of Revenue
  9.2.3 Biopta
    9.2.3.1 Overview
    9.2.3.2 Products and Services
      9.2.3.2.1 Fresh Tissue Sample Procurement
      9.2.3.2.2 Safety and Adverse Effects Testing
      9.2.3.2.3 Efficacy Testing
      9.2.3.2.4 ADME Testing
    9.2.3.3 Future Outlook
  9.2.4 BioServe
    9.2.4.1 Overview
    9.2.4.2 Products and Services
      9.2.4.2.1 Global BioRepository
      9.2.4.2.2 The BioServe Network
      9.2.4.2.3 Prospective Sample Collection
      9.2.4.2.4 DNA and RNA Extractions
      9.2.4.2.5 Genotyping
      9.2.4.2.6 Real-Time PCR
      9.2.4.2.7 DNA Synthesis
    9.2.4.3 Future Outlook
9.3 Prominent Organisations in the Umbilical Cord Blood Banking Market
  9.3.1 Cord Blood America: Looking Towards the Emerging Markets
  9.3.2 Cryo-Cell International: The First Cord Blood Bank
  9.3.3 Cryo-Save
  9.3.4 China Cord Blood Corp
  9.3.5 LifebankUSA: Placenta-Cord Banking
  9.3.6 Stem Cell Authority: Exclusive Stem Cells
  9.3.7 ViaCord: 300,000 Blood Units in Storage
9.4 Prominent Organisations in the Comprehensive Stem Cell Banking Market
  9.4.1 Biogenea
  9.4.2 StemLife
  9.4.3 Future Health Biobank
  9.4.4 NeoStem

10. QUALITATIVE ANALYSIS OF THE BIOBANKING SECTOR

10.1 Growing Demand for Biobank Resources
10.2 Industry Trends
  10.2.1Automated Biobanking
    10.2.1.1 Increased Uptake in Laboratory Information Management Systems (LIMS) in Biobanking
  10.2.2 Creation of National Biobanks
  10.2.3 Green Banking - Becoming More Energy Efficient
10.3 Strengths of the Biobanking Market, 2013
  10.3.1 Potential to Change the Field of Medicine
  10.3.2 Wealth of Information for Genetic Research
  10.3.3 Governmental Support for Biobanking
10.4 Weaknesses of the Biobanking Market, 2013
  10.4.1 A Fragmented Market
  10.4.2 Lack of Standardisation
  10.4.3 Quality Concerns for Some Existing Biospecimen Collections
10.5 Opportunities in the Biobanking Market, 2013-2023
  10.5.1 Biobank Specimens in Genome-Wide Association Studies (GWAS)
  10.5.2 Biobank Specimens in Preclinical Research
  10.5.3 The Increasing Focus on Personalised Medicine
10.6 Threats in the Biobanking Market, 2013-2023
  10.6.1 Limitations Surrounding Informed Consent
  10.6.2 Biobanks: No Guarantee of Funding
  10.6.3 Confidentiality and Security Concerns
  10.6.4 Ownership of Biospecimens
10.7 Social, Technological, Economic and Political Issues Influencing the Biobanking Market

11. RESEARCH INTERVIEWS FROM OUR SURVEY

11.1 Interview with Dr David Bunton, CEO and Co-Founder, Biopta Ltd.
  11.1.1 On the Use of Human Tissue Samples by Biopharmaceutical Companies
  11.1.2 Human Tissue vs. Stem Cells
  11.1.3 On the Technology used in Biobanks
  11.1.4 On the Future of the Biobanking Market
11.2 Interview with Dr Michael Leek, Commercial Operations Director, Pharmacells
  11.2.1 On the Recent Increase in Stem Cell Banking Activity
  11.2.2 On the Services of Pharmacells
  11.2.3 On Adult Stem Cell Banking versus Umbilical Cord Blood Banking
  11.2.4 On Challenges Facing the Stem Cell Banking Market
  11.2.5 On the Technology Used by Pharmacells
  11.2.6 On the Future of the Market
11.3 Interview with Dr Tetsuro Wakatsuki, Chief Scientific Officer, InvivoSciences Inc.
  11.3.1 On the Services Provided by InvivoSciences
  11.3.2 On the Future of this Biobanking-Associated Market
11.4 Interview with Dr Morag McFarlane, Chief Scientific Officer, Tissue Solutions
  11.4.1On the Use of Biobank Samples in the Pharmaceutical Industry
  11.4.2 On Commercial Aspects of Biobanking
  11.4.3 On the Business of Tissue Solutions
  11.4.4 On the Attractiveness of Human Tissue Banking
  11.4.5 On the Future of the Biobanking Market
11.5 Interview with Dr Angel Garcнa Martнn, Director, Inbiomed
  11.5.1 On the Importance of Biobanking in the Pharmaceutical Industry
  11.5.2 On the Use of Technology in Biobanking
  11.5.3 On Increased Recognition of Biobanking Harmonisation of Samples
  11.5.4 On the Use of Biobanks by the Pharmaceutical Industry
  11.5.5 On Private Biobanks and Scale of Operations
  11.5.6 Commercial and Public Biobanking and Legislation
  11.5.7 On the Most Attractive Segment in Commercial Biobanking
  11.5.8 On the Future of Biobanking: Drivers and Challenges
11.6 Interview with Dr Piet Smet, Director, Business Development, BioStorage Technologies
  11.6.1 On Defining Biorepositories and Biobanks
  11.6.2 On the Services of BioStorage
  11.6.3 On Main Customers for BioStorage
  11.6.4 On the Importance of Biorepositories in Research and Industry
  11.6.5 On Technology Use in Biobanks
  11.6.6 On Increased Recognition of Biobanking and Harmonisation of Samples
  11.6.7 On the Use of Biobanks by the Pharmaceutical Industry
  11.6.8 On Private Biobanks and Scale of Operations
  11.6.9 On Commercial and Public Biobanking and Legislation
  11.6.10 On the Most Attractive Segment in Commercial Biobanking
  11.6.11 On Biobanking in 2020
  11.6.12 On Drivers and Challenges in the Sector
11.7 Interview with Dr Tom Hoksbergen, Marketing and Sales, SampleNavigator Laboratory Automation Systems
  11.7.1 On the Services of SampleNavigator
  11.7.2 On Main Customers for SampleNavigator
  11.7.3 On the Importance of Biorepositories in Research and Industry
  11.7.4 On Technology Use in Biobanks
  11.7.5 On Increased Recognition of Biobanking and Harmonisation of Samples
  11.7.6 On the Use of Biobanks by the Pharmaceutical Industry
  11.7.7 On Commercial Biorepositories/ Banks and Scale of Operations
  11.7.8 On Commercial and Public Biobanking
  11.7.9 On the Most Attractive Segment in Commercial Biobanking
  11.7.10 On Biobanking in 2020
  11.7.11 On Drivers and Challenges in the Sector

12. CONCLUSIONS

12.1 World Biobanking Market Overview to 2023
12.2 The Leading National Markets
12.3 Commercial Drivers of the Biobanking Market
12.4 The Sector has Marked Challenges, but Many Opportunities for Growth

LIST OF TABLES

Table 2.1 Prominent Population-Based Biobanks, 2013
Table 2.2 Prominent Disease-Based Biobanks, 2013
Table 2.3 Guidelines and Recommendations for Biobanks, 2013
Table 2.4 Laws and Regulations for Biobank-Based Research, Consent Requirements and Privacy/ Data Protection, 2013
Table 3.1 Pharmaceutical and Biotechnology Companies with In-House Biobanks, 2013
Table 4.1 The World Medical Biobanking Market: Product Submarket Revenue, 2012
Table 4.2 World Medical Biobanking Market: Revenue Forecasts for Overall Market and Submarkets, 2012-2023
Table 5.1 Human Tissue Banking: Revenue Forecast, 2012-2023
Table 5.2 Human Tissue Banking Market by Type of Biobank, 2012
Table 5.3 Human Tissue Banking: Revenue Forecast by Type of Biobank, 2012-2023
Table 5.4 Commercial Tissue Biobanking: Revenue Forecast, 2012-2023
Table 5.5 Public Sector and Other Tissue Banks: Revenue Forecast, 2012-2023
Table 6.1 Stem Cell Banking: Overall Revenue Forecast, 2012-2023
Table 6.2 Prominent Stem Cell Banks Serving the Research Community
Table 6.3 Stem Cell Banking by Submarket, 2012
Table 6.4 Reported Fees of Various Private Cord Blood Banks
Table 6.5 Stem Cell Banking: Revenue Forecasts by Submarket, 2012-2023
Table 6.6 Revenue Forecast for the Private Cord Blood Banking Market, 2012-2023
Table 7.1 Estimated Number of Biobanks in Europe by Country, 2013
Table 7.2 The Leading National Biobanking Markets, 2012
Table 7.3 Leading National Markets: Revenue Forecasts, 2012-2023
Table 7.4 The US Biobanking Market: Revenue Forecast, 2012-2023
Table 7.5 The EU5 Biobanking Markets: Revenue Forecasts, 2012-2023
Table 7.6 The Japanese Biobanking Market: Revenue Forecast, 2012-2023
Table 7.7 The Chinese Biobanking Market: Revenue Forecast, 2012-2023
Table 7.8 The Indian Biobanking Market: Revenue Forecast, 2012-2023
Table 7.9 The Brazilian Biobanking Market: Revenue Forecast, 2012-2023
Table 7.10 The Russian Biobanking Market: Revenue Forecast, 2012-2023
Table 8.1 Prominent Companies Providing Automated Liquid Handling Technology, 2013
Table 8.2 Prominent Companies Providing Ultra-Low Temperature Freezers, 2013
Table 8.3 Prominent Manufacturers of Automated Biobanking Systems, 2013
Table 8.4 Major Vendors in the LIMS Market, 2013
Table 8.5 Prominent Consumables Suppliers for Biobanking, 2013
Table 8.6 Prominent Biorepository Service Providers, 2013
Table 9.1 Prominent Commercial Biobanks, 2013
Table 9.2 Asterand: Revenue by Geographical Area, 2011
Table 9.3 Prominent Companies in the Cord Blood Banking Market, 2013
Table 9.4 Cryo-Cell International Revenue, 2010-2012
Table 9.5 Cryo-Save: Geographical Breakdown of Revenue, 2010-2011
Table 9.6 China Cord Blood Corp: Revenue, 2011 and 2012
Table 9.7 Prominent Companies in the Extended Stem Cell Banking Market, 2013
Table 9.8 StemLife: Revenue, 9 Months to September, 2011 and 2012
Table 9.9 NeoStem: Revenue, 9 Months to 30th September, 2011 and 2012
Table 10.1 The Biobanking Market: Strengths and Weaknesses, 2013
Table 10.2 Biobanking for Medicine: Opportunities and Threats, 2013-2023
Table 10.3 Social, Technological, Economic and Political Issues Influencing the Biobanking Market (STEP Analysis), 2013
Table 12.1 The World Biobanking Market: Revenue Forecast, 2012-2023

Revenue Forecast for Private Cord Blood Banking Market, 2013-2023

In 2012, the private cord blood banking market was worth an estimated $1.62bn, made up of the revenues of the 222 private blood banks worldwide and the companies that provide the technology for them. In recent years market growth has been rapid, as the popularity of cord blood banking has spread from the US and Europe to emerging markets. In India, for example, the number of units of cord blood stem cells banked has risen from around 300 in 2004 to more than 24,000 in 2010. The increased use of cord blood in transplants has also driven interest in banking; it is estimated that more than 14,000 cord blood transplants have now been performed. Cord blood is being increasingly used as a source of stem cells in paediatric transplants. In 2000, 1% of transplants involved the use of cord blood stem cells, compared to 22% in 2010. In 2010, cord blood transplants reportedly made up 50% of all paediatric transplants.

Between 2012 and 2017, revenues of existing blood banks are expected to see high annual growth. The main driver of this market is the increasing use of umbilical cord blood as an alternative to adult sources of haematopoietic stem cells, such as bone marrow. Double cord transplants are often used in adult patients, resulting in a high demand for umbilical cord blood. In light of this high demand, the UK government has recommended an increase in the number of umbilical cord blood units stored. Market growth will also be driven by new banks opening, providing access to a greater number of potential consumers. Emerging markets will continue to provide a strong source of revenue growth. Sales are likely to reach $2.63bn by 2017, representing a CAGR of 10.2%. 

From 2017 to 2023 worldwide revenues in the private blood banking market are expected to slow, as the market gains maturity and stabilizes, with growth at a CAGR of 5.8%. Further growth in the market is dependent on the development of stem cell technologies. Without improvements to stem cell technologies that allow autologous cord blood stem cell transplants to be the optimal treatment option – rather than the last resort they currently are – growth in the private blood banking market will be restrained. The market will generate revenue of $3.77bn in 2023.



More Publications